148 related articles for article (PubMed ID: 19456231)
1. Fragmented tissue factor pathway inhibitor (TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures.
Schirm S; Liu X; Jennings LL; Jedrzejewski P; Dai Y; Hardy S
J Infect Dis; 2009 Jun; 199(12):1807-15. PubMed ID: 19456231
[TBL] [Abstract][Full Text] [Related]
2. Proteolysis of tissue factor pathway inhibitor (TFPI) by plasmin: effect on TFPI activity.
Li A; Wun TC
Thromb Haemost; 1998 Sep; 80(3):423-7. PubMed ID: 9759622
[TBL] [Abstract][Full Text] [Related]
3. Oxidized low-density lipoprotein associates strongly with carboxy-terminal domain of tissue factor pathway inhibitor and reduces the catalytic activity of the protein.
Horie S; Hiraishi S; Hamuro T; Kamikubo Y; Matsuda J
Thromb Haemost; 2002 Jan; 87(1):80-5. PubMed ID: 11848461
[TBL] [Abstract][Full Text] [Related]
4. [Generation of recombinant human tissue factor pathway inhibitor in E. coli].
Leng X; Wang C; Song L; Li X; Ma J; Wang P
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2003 Jun; 20(2):314-7. PubMed ID: 12856608
[TBL] [Abstract][Full Text] [Related]
5. Vertebrate TFPI-2 C-terminal peptides exert therapeutic applications against Gram-negative infections.
Kasetty G; Smeds E; Holmberg E; Wrange L; Adikesavan S; Papareddy P
BMC Microbiol; 2016 Jun; 16(1):129. PubMed ID: 27349742
[TBL] [Abstract][Full Text] [Related]
6. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Enjyoji K; Miyata T; Kamikubo Y; Kato H
Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8.
Cunningham AC; Hasty KA; Enghild JJ; Mast AE
Biochem J; 2002 Oct; 367(Pt 2):451-8. PubMed ID: 12117418
[TBL] [Abstract][Full Text] [Related]
8. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock.
Carr C; Bild GS; Chang AC; Peer GT; Palmier MO; Frazier RB; Gustafson ME; Wun TC; Creasey AA; Hinshaw LB
Circ Shock; 1994 Nov; 44(3):126-37. PubMed ID: 7600636
[TBL] [Abstract][Full Text] [Related]
9. Recombinant tissue factor pathway inhibitor enhances the binding of factor Xa to human monocytes.
Li A; Chang AC; Peer GT; Wun TC; Taylor FB
Thromb Haemost; 2001 May; 85(5):830-6. PubMed ID: 11372676
[TBL] [Abstract][Full Text] [Related]
10. Regulation of thrombin generation by TFPI in plasma without and with heparin.
Brodin E; Appelbom H; Osterud B; Hilden I; Petersen LC; Hansen JB
Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095
[TBL] [Abstract][Full Text] [Related]
11. Tissue factor pathway inhibitor: structure, biology and involvement in disease.
Lwaleed BA; Bass PS
J Pathol; 2006 Feb; 208(3):327-39. PubMed ID: 16261634
[TBL] [Abstract][Full Text] [Related]
12. HVJ-AVE liposome-mediated Tissue Factor Pathway Inhibitor (TFPI) gene transfer with recombinant TFPI (rTFPI) irrigation attenuates restenosis in atherosclerotic arteries.
Yin X; Fu Y; Yutani C; Ikeda Y; Enjyoji K; Kato H
Int J Cardiol; 2009 Jun; 135(2):245-8. PubMed ID: 18590936
[TBL] [Abstract][Full Text] [Related]
13. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli--a comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli.
Randolph MM; White GL; Kosanke SD; Bild G; Carr C; Galluppi G; Hinshaw LB; Taylor FB
Thromb Haemost; 1998 May; 79(5):1048-53. PubMed ID: 9609245
[TBL] [Abstract][Full Text] [Related]
14. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
15. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells.
Kamikubo Y; Nakahara Y; Takemoto S; Hamuro T; Miyamoto S; Funatsu A
FEBS Lett; 1997 Apr; 407(1):116-20. PubMed ID: 9141493
[TBL] [Abstract][Full Text] [Related]
16. Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo.
Liang W; Cheng J; Liu R; Wang JP; Mu JG; Wang QH; Wang HJ; Ma D
Peptides; 2009 Dec; 30(12):2330-6. PubMed ID: 19720104
[TBL] [Abstract][Full Text] [Related]
17. The tissue factor pathway inhibitor 1 of Sciaenops ocellatus possesses antimicrobial activity and is involved in the immune response against bacterial infection.
Zhang M; Sun L
Dev Comp Immunol; 2011 Mar; 35(3):247-52. PubMed ID: 20970444
[TBL] [Abstract][Full Text] [Related]
18. Anti-complement effects of lactoferrin-derived peptides.
Samuelsen Ø; Haukland HH; Ulvatne H; Vorland LH
FEMS Immunol Med Microbiol; 2004 Jun; 41(2):141-8. PubMed ID: 15145458
[TBL] [Abstract][Full Text] [Related]
19. Hemoglobin and its derived peptides may play a role in the antibacterial mechanism of the vagina.
Deng L; Pan X; Wang Y; Wang L; Zhou XE; Li M; Feng Y; Wu Q; Wang B; Huang N
Hum Reprod; 2009 Jan; 24(1):211-8. PubMed ID: 18786935
[TBL] [Abstract][Full Text] [Related]
20. The classical complement pathway plays a critical role in the opsonisation of uropathogenic Escherichia coli.
Li K; Sacks SH; Sheerin NS
Mol Immunol; 2008 Feb; 45(4):954-62. PubMed ID: 17870166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
